Morgan Stanley’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Morgan Stanley’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,300	Closed	-$43	–	7809
2023 Q1	$43	Hold	1,300	–	–	﹤0.01%	7617
2022 Q4	$72	Hold	1,300	–	–	﹤0.01%	7716
2022 Q3	$0	Hold	1,300	–	–	﹤0.01%	8035
2022 Q2	$0	Hold	1,300	–	–	﹤0.01%	8133
2022 Q1	$0	Hold	1,300	–	–	﹤0.01%	8252
2021 Q4	$1K	Hold	1,300	–	–	﹤0.01%	7922
2021 Q3	$1K	Hold	1,300	–	–	﹤0.01%	7854
2021 Q2	$1K	Buy	+1,300	New	+$1.17K	﹤0.01%	7671

Morgan Stanley's EUCRW Position: Q2 2023 in Review

Morgan Stanley sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 1,300 shares — an estimated $43 sold.

Morgan Stanley first reported a position in EUCRW in Q2 2021 and held it in 8 quarters. The position peaked at $1K in Q4 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Morgan Stanley reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Morgan Stanley sold 1,300 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $43.
Morgan Stanley first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q2 2021 and held it in 8 quarters.
Morgan Stanley's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $1K in Q4 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.